In November 2018, Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) released the first package of 38 products with cannabis and its derivatives, which will benefit the Mexican capital company CBD Science, which is already ready to commercialize their products on Internet, then reach drugstores and supermarkets.

The firm obtained five permissions from Cofepris to commercialize three products based on hemp oil with different concentrations of Cannabidiol (CBD) of 250, 500 and 1,000 milligrams, as well as a jar of 30 capsules with 25 milligrams each.

"For the classification that gave us the Cofepris food supplement, by law we cannot give any therapeutic action, but for uses and customs the cannabis products are auxiliary in symptoms of pain, inflammation and insomnia," said Pablo Botella, CEO of CBD Science, in an interview with Forbes Mexico.

In a first stage, the plan of CBD Science is to import the finished product from the United States, to sell it in the first months of 2019, while in a second phase they expect to begin production and process of raw material in Mexico, which would be given for the second half of this year.

Login to Digital Content

Subscribe to our Newsletter Bulletin